ClinicalTrials.gg
CompletedNCT01858896Updated Nov 6, 2026

GLP-1 and Hypoglycemia

An Early Phase 1 interventional study of Glucagon-Like Peptide- 1 (GLP-1) infusion and Placebo Comparator: Saline Infusion in Type 2 Diabetes Mellitus, sponsored by University of Maryland, Baltimore. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University of Maryland, Baltimore · Early Phase 1, Interventional, and Treatment

How we know

Updated Nov 6, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies testing Glucagon-Like Peptide 1 in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Glucagon-Like Peptide 1 · Diabetes Mellitus, Type 2.

Planned enrollment
5th of 11
28 · median 20
Started
2013
with 1 other
Phase 1
Only one
of the 11
Registered
9th of 11
by date
Lead sponsor
1 of 11
University of Maryland, Baltimore

Among the 11 studies testing Glucagon-Like Peptide 1 in Diabetes Mellitus, Type 2, this one is the 5th largest by planned enrollment, is one of 2 that started in 2013, is the only one in phase 1, and was the 9th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 11 studies testing Glucagon-Like Peptide 1 in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Glucagon-Like Peptide 1

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Glucagon-Like Peptide 1 in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Low blood sugar can negatively affect how blood vessels function, and this can lead to an increase in the risk for heart attacks, strokes and other problems related to the stiffening and blockage of blood vessels. The purpose of this study is to learn if and how glucagon-like peptide-1 (GLP-1; a naturally occurring hormone in the gut) changes the effects that low blood sugar levels have on blood vessels.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • hypoglycemia
  • GLP-1
  • Type 2 diabetes
  • endothelial function
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 14 (7 males, 7 females) healthy controls age 30-60 yr.
  • 14 (7 males, 7 females) people with type 2 DM age 30-60 yr.
  • For type 2 DM: 6-10.0%
  • No significant diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc.)
  • >25kg • m-2

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
28 participants (estimated)

Study arms

  • Active comparator
    Glucagon-Like Peptide -1 (GLP-1) infusion

    Infusion of GLP-1 during experimental period

    Drug: Glucagon-Like Peptide- 1 (GLP-1) infusion

  • Placebo comparator
    Saline Infusion

    Saline infusion during experimental period

    Other: Placebo Comparator: Saline Infusion

Interventions

  • DrugGlucagon-Like Peptide 1Studies of Glucagon-Like Peptide 1Glucagon-Like Peptide 1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    GLP-1 infusion during experimental period

    Also known as: GLP-1

  • OtherPlacebo Comparator: Saline Infusion

    Saline infusion (placebo) during experimental period

    Also known as: Saline infusion

06

What researchers measure

Primary outcomes

  1. Change in Plasminogen Activation inhibitor-1 (PAi-1)

    measurements of change in PAi-1 at baseline and during the end of the glucose clamp period (2 hours)

    Time frame: change from baseline to end of clamp period

  2. Change in Flow mediated dilation (FMD)

    flow mediated dilation of the brachial artery will be measured for change from baseline and end of glucose clamp (\~4 hours)

    Time frame: change from baseline and end of clamp

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Feb 2026, 151 months.

Of 63 non-industry phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's 151 months is above that.

Counting every sponsor, half of 517 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Sep 2026 → Feb 2026 and completion Dec 2026 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2013
First posted
May 21, 2013
StartActual
Jul 2013
Primary completionActual
Feb 26, 2026was Sep 2026
CompletionActual
Feb 26, 2026was Dec 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 6, 2026
Primary completion
Sep 2026→Feb 26, 2026 (actual)
Nov 6, 2026
Study completion
Dec 2026→Feb 26, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Active, not recruiting→Completed
    Primary completion Sep 2026→Feb 26, 2026 (now actual)
    Study completion Dec 2026→Feb 26, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT01858896
Responsible party
Stephen N. Davis, MBBS (Chairman of Medicine, University of Maryland, Baltimore) — Principal investigator
First posted
May 21, 2013
Start date
Jul 2013
Primary completion
Feb 26, 2026
Completion
Feb 26, 2026
Last update
Nov 6, 2026

Study contacts

Stephen N Davis, MBBS
principal investigator · University of Maryland, Baltimore

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glucagon-Like Peptide 1

Start the discussion